We are international
Donate
TEXT SIZE   


Thalidomide Editorial
The IMF responds via a letter to the editor to several US newspapers that ran articles regarding the use of thalidomide in treating myeloma.
09.21.01

Dear Editor:

The International Myeloma Foundation (IMF) applauds the Daily Oklahoman for its recent article regarding the use of thalidomide in treating multiple myeloma, a fatal bone marrow cancer that affects more than 75,000 people in the United States. Multiple myeloma is on the rise, with an estimated 13,700 new cases being diagnosed each year. As the numbers continue to climb, it is imperative that ongoing research be conducted in the search for new treatment options, and ultimately a cure for myeloma.

Relying on recommendations made by the IMF, Congress recently urged the National Cancer Institute (NCI) to support promising research and encourage new investigators into the field of multiple myeloma. Thanks to this unprecedented act of congressional support, we are confident that we will see significant advances in multiple myeloma research activities throughout the coming year.

The International Myeloma Foundation has a ten-year history of supporting the research, education, advocacy and treatment of myeloma. We exist to provide patients, their families and the medical community with the information and resources they need to make educated treatment decisions. Contact us at (323) 654-3023 or via our toll-free hotline at (800) 452-CURE. We also can be found on the Internet at www.myeloma.org.

Again, thank you for your efforts to raise awareness of multiple myeloma and the new and innovative treatment options available to patients.

Best regards,



Susie Novis, President
International Myeloma Foundation
12650 Riverside Drive, Ste. 206
North Hollywood, CA 91607
(818) 487-7455


 related articles